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1. Introduction 
Vigorous development of immunology and immunopharmacology is closely interrelated 
with formation of new scientific “branches”of neuroimmunology and 
neuroimmunopathology which predetermines the hypotheses of mutual regulation-
interaction of the nervous and immune systems, of the significance of neuroimmune 
mechanisms in the regulation of most physiological functions and development of 
pathophysiological processes (Alford L., 2007; Irwin M.R., 2008; Freund G.G., 2009). The 
formulated hypotheses that immunologic mechanisms are involved in the pathogenesis of 
the CNS diseases (stroke, multiple sclerosis, chronic fatigue syndrome, epilepsy, etc.), their 
systematization within the scope of special neuroimmunipathology have laid the 
groundwork for a vigorous pharmacological search of agents for eliminating neuroimmune 
disturbances (Kryzhanovsky G.N. et al., 2003; Fleshner M., Laudenslager M.L., 2004; 
Alexandrovsky Y.A., Chekhonin V.P., 2005; Samotrueva M.A. et al., 2009).  
In light of this problem and considering the abundant factual material testifying to the 
involvement of GABAergic system in immunomodulation, substances which are GABA 
analogues become of particular interest (Devoyno L.V., Iliuchenok R.U., 1993; Korneva E.A., 
2003). Thus, in this experimental work we studied the immunotropic properties of the known 
representatives of group of GABAergic agents such as phenotropil (N-carbamoyl-methyl-4-
phenyl-2-pyrrolidone), phenibut (hydrochloride of Ǆ-amino and ǃ-phenylbutyric acids) and 
baclofen (Ǆ-amino-para-chloro-ǃ-phenylbutyric acid). Having a wide range of psychotropic 
effects these drugs improve cognitive activity, decrease emotional tension and anxiety, 
normalize sleep; diminish asthenic manifestations, vasovegetative symptoms, etc. (Arushanian 
E. B., 2004). In this work aiming to widen the activity range of the above-mentioned drugs as 
well as to search for drugs capable of eliminating immune imbalance which is often in causal 
relationship with the CNS pathologies we studied the immunomodulating activity of gamma-
aminobutyric acid (GABA) derivatives using an experimental immunosuppression model and 
determined the most effective doses and regimens.  
2. Materials and methods 
The study was performed on 544 CBA-line mice both male and female aged 3-4 months 
weighing 20-25g. The animals were kept in standard vivarium conditions – in plastic cages 
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on a sawdust bedding at a room temperature of +18-22°. They were fed twice a day with 
natural foods in the amount corresponding to daily doses (P 50258-92 State Standard) had a 
free access to water. The lighting in the daytime (12 hours) was combined (natural and 
luminescent). The animals were kept according to the guidelines on laboratory practice for 
preclinical trials in the RF (З 51000.3-96 and 51000.4-96 State Standards) and the Order of the 
Health Care Ministry of the RF № 267 of 19.06.2003 ‘On the Approval of the Guidelines on 
Laboratory Practice’ (GLP) as well as in conformity with the International recommendations 
of the European Convention for the Protection of Vertebrae Animals Used for Experimental 
and Scientific Purposes, 1997. 
By the moment when the experiments were held the animals had adapted to the human 
factor, acclimatized and were in good health (no changes in behaviour, appetite, circadian 
cycle, condition of fur and visible mucosas were detected). All the experiments were carried 
out in the spring-autumn period (without abrupt changes of weather conditions) within one 
and the same time interval (from 11.00 till 19.00 ) to avoid the influence daily biorhythms on 
the investigation results. The rodents were euthanized by means of fast cervical dislocation. 
The pathology of the immune system was simulated by a single intraperitoneal introduction 
of cyclophosphamide (CPA) in a dose of 150 mg/kg 1 hour after the immunization with 
sheep erythrocytes (SE) (Arkadyev V.G. et al., 2003). The investigated substances were 
introduced 1 hour after the immunodepressant (“Biochimik”, Russia). 
The model of cyclophosphamide (CPA) immunosuppression was used to estimate the 
immunocorrective properties of phenotropil, phenibut and baclofen in a “dose-effect” 
respect, when administered intraperitoneally as a single dose and introduced during a 
peroral course of treatment; to study the immunopreventive and/or immunotherapeutic 
aspects of the action of the drugs when administered at different times in relation to CPA 
immunosuppression introduction (“time-effect”). 
2.1 Immunopharmacological tests 
The immune status of the animals was evaluated on the basis of standard 
immunopharmacological tests: delayed hypersensitivity reaction (DHR) involving the 
reaction index definition, passive hemagglutination reaction (PHAR) involving the antibody 
titre definition, latex test to study the phagocytic activity of peripheral blood neutrophils as 
well as a leukogram, to define the weight and cellularity of immunocompetent organs 
(thymus, spleen) (Khaitov R.M. et al., 2005). 
The DHR was used to evaluate a cellular link of the primary immune response to sheep 
erythrocytes (SE). The animals of all groups were immunized by receiving a single 
hypodermic SE injection (a sensibilizing injection) (2x108) in the interscapular area. The antigen 
booster dose was introduced on the 5th day (1x108 SE) in 0,02 ml of physiological saline into a 
hind leg paw – “experimental” leg (the booster injection). The equivalent amount of 
physiological saline was introduced into the contralateral leg – “control” leg. The reaction was 
estimated 24 hours later by euthanizing the animals by fast cervical dislocation, after which 
both legs were cut off at the level of an ankle-joint and weighed using analytical balances. The 
reaction index (DHRI) was calculated using the formula: RI = (Mex — Mc)/Mc x 100%, where 
RI is a reaction index, Mex is an “experimental” leg weight; Mc is “control” leg weight. 
PHAR was used to estimate the humoral link of the primary immune response to SE. The 
animals were immunized once intraperitoneally in a dose of 5x108 in the amount of 500 mcl 
1-2 hours after the introduction of the investigated substance. 7 days later the animals were 
withdrawn from the experiment by administering serum. To inactivate the complement the 
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serum was heated for 30 min at a temperature of 56°C. The hemagglutination reaction was 
carried out in 96-well plates in the amount of 500 mcl of a diluent (0.5% solution of bovine 
serum albumin (BSA), solved in physiological saline) in which the investigated serums were 
successively diluted twice. After the dilution of the serums 25 mcl of 1% SE suspension was 
introduced into each well. The preliminary analysis of the PHAR results was done after one 
hour of incubation at a temperature of 37C°, the plates were placed into a refrigerator and 
kept at a temperature of +4°C. The reaction was finally evaluated 18 hours later. The 
antibody titre (the maximal serum dilution in which SE agglutination was registered) was 
indicated using average compound indices. 
To estimate the phagocytic activity of neutrophils the animals’ heparinized blood was used. A 
suspension of latex particles of 1.3-1.5 µm size (“MinMedBioprom”, Russia) was prepared in 
advance. The original latex suspension was three times washed with a 0.9% NaCl solution at 
3000 rpm for 10 minutes. The sediment was resuspended in medium 199, the number of 
particles was calculated in a Goryaev’s chamber and brought to the ultimate concentration 
of 150000 in 1mcl. 24-48 hours after the introduction of the investigated substances (in the 
control group it was physiological saline) the animals were withdrawn from the experiment 
and their blood samples were taken. 50 mcl of the latex work solution was mixed with 50 
mcl of heparinized blood and placed into a temperature-regulated chamber at a temperature 
of 37°C. The test-tubes were shaken by hand every ten minutes and then centrifuged. 
Smears were taken from the sediment, they were dried and fixed in Nikiforov’s mixture 
consisting of equal parts of absolute ethyl alcohol and ether (10 min). The next day they 
were stained by the Romanovsky-Giemsa method (20-30 min). After this the smears were 
washed with water and dried in the air. The stained smears were examined under a 
microscope in an immerse system. The number of leucocytes and neutrophils with latex and 
without it was calculated in a smear. At the same time the number of latex particles in 
neutrophils was counted. The phagocytic activity of neutrophils was evaluated on the basis 
of the following indices: phagocytic index (% of phagocytosis) – the number of neutrophils 
with latex in 100; phagocytic count = the number of latex particles/100.  
The total leukocyte count was calculated in a Goryaev’s chamber. 0.4 ml of a diluent (3-5% of 
acetic acid dyed with methylene blue (acetic acid lyses erythrocytes, methylene blue stains 
leukocyte nuclei)) and 0.02 ml of blood was placed in a test-tube. Leukocytes were counted 
in 100 large squares. The total leukocyte count was calculated using the formula: X = A x 50, 
where X is the number of leukocytes in 1mcl of blood, A is the number of leukocytes 
calculated in a Goryaev’s chamber. 
A blood leukogram was calculated in blood smears stained by the Romanovsky-Giemsa 
method. The count of neutrophils (stab and segmented neutrophils), eosinophils, 
monocytes, and lymphocytes was calculated in a smear. 
Lymphoproliferative processes in the immunocompetent organs were determined on the basis 
of the weight and cellularity of the thymus and spleen. After the animals were euthanized, 
the organs were extracted and weighed; cell suspensions were prepared in medium 199 
with 50 mg/ml concentration for the spleen and 10 mg/ml for the thymus. They were 
filtrated, washed twice with medium 199 to remove adipose tissue particles (for 10 min at a 
rate of 1500 revolutions). After that they were resuspended in medium 199 to the original 
concentration in medium 199. To make calculations the suspensions of lymphoid organs 
were previously mixed in the ratio 1:1 with 3% acetic acid, dyed with methylene blue; the 
number of nucleated cells (NC) was counted in a Goryaev’s chamber. The number of NC was 
indicated in absolute and relative (in relation to the weight of the lymphoid organ) values. 
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2.2 Experimental series and groups 
A few sets of experiments were carried out: the 1st aimed to study the immunomodulating 
activity of GABA derivatives in a “dose-effect” respect; the 2nd st explored the 
immunopreventive and/or immunotherapeutic aspects of the effect of GABA derivatives 
when administered at different times in relation to CPA immunosuppression introduction 
(“time-effect”); the 3rd targeted to evaluate the activity of GABA derivatives when 
introduced during a peroral course of treatment; the 4th aimed to study the capability of the 
substances to eliminate leukogram disturbances and to restore lymphoproliferative and 
biochemical processes in the immunocompetent organs (thymus, spleen). 
The animals in each set of experiments were divided into groups (n=8): control 1 was 
represented by mice receiving physiological saline as a placebo in the equivalent amount 
(similarly to the way and frequency of administration of the investigated substance in each 
set); control 2 included species with an immunopathology model, they also received 
physiological saline; experimental groups included animals with immunosuppression, 
which received GABA derivatives in accordance with the goal pursued in each set of 
experiments.  
In the 1st and 3rd experimental sets CPA was introduced 1 hour after the immunization with 
SE to the animals of the control 2 group and experimental groups; in the 2nd set CPA was 
administered twice (simultaneously with the immunization and 24 hours after the 
immunization with SE). 
3. Results and discussion 
3.1 Immunosupression 
All the conducted experimental sets proved the development of immunological 
insufficiency in the control 2 group mice: a reliable decrease by more than 50% in the DHR 
index, by more than 35% in the hemagglutin titre, by more than 40% in the neutrophil 
phagocytic activity as compared to the similar indicators in the control 1 group was 
observed. Moreover, depressed leucopoiesis manifesting itself both as a statistically relevant 
decrease of the total leukocyte count (by more than 20% with p1<0.05) and a pronounced 
change in the cell ratio in the leukogram was registered in the animals exposed to CPA 
cytostatic drug. Particularly, a reliable decrease by more than 30 % in the count of 
leukocytes and segmented neutrophil leukocytes as compared to the background values in 
control 1 (p1<0.05) and a total absence of eosinophils were observed in CPA 
immunosuppression. It should be noted that the number of stab neutrophils was more than 
50% higher (p1<0.05) in this group of mice. The study of lymphoproliferative and 
biochemical processes in the immunocompetent organs revealed involution of the thymus 
and spleen and a decreased cell count in them (p1<0.05), as well as a reliable increase in the 
lipid peroxidation intensity associated with decreased catalase activity in the investigated 
organs (p1<0.05). 
3.2 The immunomodulating activity of GABA derivatives in a “dose-effect” respect 
In the 1st experimental set the model CPA immunosuppression was used to study the 
activity of phenotropil, phenibut, and baclofen in the following doses: phenotropil – 25 
mg/kg; 50 mg/kg; 100 mg/kg; phenibut –12.5 mg/kg; 25 mg/kg; 50 mg/kg; 100 mg/kg 
and baclofen – 2 mg/kg; 5 mg/kg; 10 mg/kg; 20 mg/kg (Samotrueva M.A. et al., 2010; 
Tyurenkov I.N. et al., 2008, 2009, 2010). 
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The conducted investigation demonstrated that a single intraperitoneal introduction of 
phenotropil in all studied doses promoted an over 50% restoration of the indices of cellular 
DHR and the level of antired-cell antibodies in PHAR as compared to the corresponding 
values in the animals with simulated immunopathology (p2<0.05) (here and below p1 and p2 
– are reliability degrees in the relatively intact animals and animals with 
immunosuppression correspondingly). Moreover, phenotropil introduced in doses of 
25mg/kg and 50 mg/kg showed pronounced immunostimulating properties regarding 
DHR: the quantitative parameter of the local reaction was statistically reliably higher than 
that of control 1 (p1<0.05). Phenotropil in a dose of 100 mg/kg had a less pronounced 
immunocorrective action in relation to the humoral and cellular immunity links: the 
indices of DHRI and the antibody titre were 30-40% higher than those in the 
immunosuppressed species (p2<0.05). However, they did not exceed the values in the 
intact animals (fig. 1).  
 
 
 
Experimental groups: 1 - control 1 (physiological saline); 2 - control 2 (CPA); 3 – phenotropil (25mg/kg) + 
CPA; 4 – phenotropil (50mg/kg) + CPA; 5 – phenotropil (100 mg/kg) + CPA 
Notes: Δ and * – p<0.05 <– reliability of differences as compared to controls 1 and 2 correspondingly 
(Student’s t-criterion with Bonferroni and Newman-Keuls’ adjustment for multiple comparisons, single-
factor analysis of variance involving the definition of Tukey-Kramer criterion and Scheffe’s criterion) 
In what follows: DHRI – delayed hypersensitivity reaction index, PHAR – passive hemagglutination 
reaction, PI – phagocytic index, PC – phagocytic count. 
Fig. 1. Effect of phenotropil in different doses on PHAR, DHR development and the 
phagocytic activity of neutrophils in the immunosuppression conditions 
The evaluation of phenotropil effect on the indices of the non-specific link of 
immunogenesis in the conditions of CPA-induced immunosuppression revealed that the 
drug eliminated the inhibiting action of the immunodepressant. A statistically reliable 
increase of PI (by more than 20%) when phenotropil was introduced in doses of 25 mg/kg 
(p2<0.05) and 50 mg/kg (p2<0.001) and PC (by more than 20%) in doses of 25 mg/kg 
(p2<0.05) and 100 mg/kg (p2<0.05) as compared to the immunosuppressed animals was 
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registered. The administration of phenotropil in a dose of 25 mg/kg was associated with a 
restoration of the indices demonstrating the phagocytic activity of neutrophils almost to the 
“norm” (fig. 1). 
Proceeding from the obtained results we selected the doses of 25 mg/kg and 50 mg/kg for a 
further study of phenotropil as an immunocorrective drug.  
The administration of phenibut in doses of 25 mg/kg and 50 mg/kg was associated with a 
rise by more than 80% in the indices of both specific (the antibody titre in PHAR and the 
DHR index) and non-specific (PI and PC) immunoreactivity as compared to the similar 
values in the group of animals with simulated immunopathology (control 2) (p2<0.05) and a 
rise by more than 20% as compared to control 1 (p1<0.05) which proves the 
immunostimulating properties of phenibut in the specified doses (fig. 2).  
A single intraperitoneal introduction of phenibut in a dose of 100 mg/kg promoted the 
elimination of CPA suppressor effect on the development of a primary immune response to 
SE: antibody titre in PHAR and DHRI reached the background values in the placebo control 
(p2<0.05). No reliably significant change in phagocytosis indices induced by phenibut 
administration in a dose of 100 mg/kg was registered which proves that in this dose the 
drug has no corrective effect in respect to nonspecific resistance. A dose of 12.5mg/kg of the 
investigated substance appeared to be effective only with respect to the humoral link of 
pathogenesis: antibody titre in PHAR almost reached “the norm” values in control 1 
(p2<0.05) (fig. 2). 
 
 
Experimental groups: 1 - control 1 (physiological saline); 2 - control 2 (CPA); 3 – phenibut (12.5 mg/kg) + 
CPA; 4 – phenibut (25 mg/kg) + CPA; 5 – phenibut (50 mg/kg) + CPA; 6 – phenibut (100 mg/kg) + 
CPA. 
Notes: Δ and * – p<0.05 <– reliability of differences as compared to controls 1 and 2 correspondingly 
(Student’s t-criterion with Bonferroni and Newman-Keuls’ adjustment for multiple comparisons, single-
factor analysis of variance involving the definition of Tukey-Kramer criterion and Scheffe’s criterion) 
Fig. 2. Effect of phenibut in different doses on PHAR, DHR development and the phagocytic 
activity of neutrophils in the immunosuppression conditions 
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Therefore, the most significant immunoreactivity changes in the animals with experimental 
immunosuppression were observed when phenibut was administered in doses of 25 mg/kg 
and 50 mg/kg which were recommended for a further study of the immunomodulating 
activity of phenibut. 
The evaluation of the immunocorrective properties of baclofen using a CPA 
immunosuppression model revealed that the introduction of the drug in doses of 2 mg/kg, 
5 mg/kg, and 10 mg/kg had a modulating effect on antibody formation (p2<0.05). In 
addition, the most pronounced increase of the antibody titre in PHAR was registered in a 
dose of 10 mg/kg; the studied index was 2.5 times as high as that in the species with an 
immune pathology while the administration of baclofen in doses of 2 mg/kg and 5 mg/kg 
increased the index by no more than 60% (p2<0.05). A dose of 20 mg/kg proved to be 
ineffective: the antibody titre in PHAR was similar to that in the animals with 
immunosuppression (p2<0.05) (fig. 3). 
 
 
Experimental groups: 1 - control 1 (physiological saline); 2 - control 2 (CPA); 3 – baclofen (2 mg/kg) + 
CPA; 4 – baclofen (5 mg/kg) + CPA; 5 – baclofen (10 mg/kg) + CPA; 6 – baclofen (20 mg/kg) + CPA. 
Notes: Δ and * – p<0.05 – reliability of differences as compared to controls 1 and 2 correspondingly 
(Student’s t-criterion with Bonferroni and Newman-Keuls’ adjustment for multiple comparisons, single-
factor analysis of variance involving the definition of Tukey-Kramer criterion and Scheffe’s criterion) 
Fig. 3. Effect of baclofen in different doses on PHAR, DHR development and the phagocytic 
activity of neutrophils in the immunosuppression conditions 
As for the cellular link of immunogenesis baclofen was active in doses of 2 mg/kg, 5 mg/kg, 
and 10 mg/kg. The most significant changes in the DHRI were registered when the drug 
was administered in doses of 2 mg/kg and 10 mg/kg: the studied index exceeded that in the 
group of animals with an immune pathology by more than 80% at that. Moreover, baclofen 
in a dose of 2 mg/kg had a stimulating effect on a cellular immune response increasing the 
DHRI by 20% as compared to the intact animals. It should be noted that as a dose of 
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baclofen increased to 20 mg/kg, no corrective action of the drug on DHR development was 
observed while the CPA’s immunoinhibiting effect intensified (CPA).  
The results which demonstrate the effect of baclofen in different doses on the indices of the 
phagocytic activity of neutrophils are of particular interest. We found that regarding this 
index the drug had a dose-dependent effect: as a dose of baclofen increased from 2 mg/kg 
to 20 mg/kg its corrective action declined. Thus, when it was administered in a dose of 2 
mg/kg phagocytosis activity increased by more than 35% as compared to the 
immunosuppressed animals (p2<0.05); while in doses of 5 mg/kg and 10 mg/kg this index 
increased only by 10-20% (p2<0.05); and in a dose of 20 mg/kg a slight increase of CPA 
immunosuppressive activity was registered (fig. 3). Therefore, proceeding from the analysis 
results a baclofen dose of 2 mg/kg was chosen for further research as the most active. 
3.3 The immunopreventive and/or immunotherapeutic aspects of the effect of GABA 
derivatives  
In the second set of experiments we explored the activity of phenotropil, phenibut, and 
baclofen using the CPA-induced immunosuppression model in a “time-effect” respect to 
reveal the immunopreventive and/or immunotherapeutic aspects of the action of the drugs 
(Samotrueva M.A. et al., 2009; Tyurenkov I.N. et al., 2010). 
 
 
Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA); 3 – phenotropil (preventive 
administration) + CPA; 4 – phenotropil (at immunosuppression induction) + CPA; 5 – phenotropil 
(therapeutic administration) + CPA 
Designations: * – p<0.05 reliable difference of findings in experimental groups in comparison with 
control 2; Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction, Tukey-Kramer one-way ANOVA) 
Fig. 4. Effect of phenotropil on the formation of DHR, PHAR and on phagocytic activity of 
neutrophils when administered at different times in relation to immunosuppression 
induction 
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The evaluation of the immunocorrective properties of phenotropil administered 
intraperitoneally for three times before antigen stimulation and/or immunosuppression 
induction revealed that the drug proved capable of preventing the disturbances of the 
cellular and humoral immunity links, as well as of the phagocytic activity of neutrophils 
induced by CPA. Thus, the DHR index and the level of antired-cell antibodies in the animals 
of the experimental group were more than 50% higher than the corresponding indices in the 
immunosuppressed species (p2<0.05) approximating the immune response parameters in 
the control 1 group (p1<0.05). The number of cells involved in the non-specific body defense 
(PI) and phagocytosis intensity (PC) in the animals receiving phenotropil before the 
immunosuppression induction was also restored (p2<0.05) almost reaching the “norm” 
indices in control 1 (fig. 4). 
 
 
Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA); 3 – phenibut (preventive 
administration) + CPA; 4 – phenibut (at immunosuppression induction) + CPA; 5 – phenibut 
(therapeutic administration) + CPA 
Designations: * – p<0.05 reliable difference of findings in experimental groups in comparison with 
control 2; Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction, Tukey-Kramer one-way ANOVA) 
Fig. 5. Effect of phenibut on the formation of DHR, PHAR and on phagocyric activity of 
neutrophils when administered at different times in relation to immunosuppression 
induction 
The introduction of phenotropil after the immunization and/or immunosuppression 
induction contributed to the restoration of only the humoral link of immunogenesis: the 
level of serum antibodies in the experimental animals was more than 60% higher than that 
of the immunosuppressed species (p2<0.05). No restoration of the cellular immunity link 
and phagocytic activity of neutrophils affected by phenotropil administered, when 
immunosuppression had already developed, was observed: DHR index, PI, and PC 
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remained similar to the indices of the animals with an immune system pathology (p2<0.05) 
(fig. 4). 
Thus the therapeutic effect of phenotropil, once immunosuppression has been induced, is 
only manifested in relation to the humoral link of immune reactivity. However if the drug is 
administered prior to antigen stimulation and / or immunosuppression induction, this 
allows avoidance of immunological insufficiency development manifested by suppression 
of the activity of all links of immunogenesis, which indicates that phenotropil displays a 
therapeutic immunocorrective action.  
Studying the time-effect aspect of the properties of phenibut demonstrated that the drug 
displays an ability to eliminate the immunosuppressive effect of CPA upon its 
administration during the induction phase of immunogeneis (that is, on the first day of 
antigen stimulation), and simultaneously with induction of immunopathology: the indices 
of cellular and humoral immune response in mice exceeded similar indices more than twice 
(p2<0.05) both in immunosuppressed animals and in intact ones (fig. 5). 
 
 
Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA); 3 – baclofen (preventive 
administration) + CPA; 4 – baclofen (at immunosuppression induction) + CPA; 5 – baclofen (therapeutic 
administration) + CPA 
Designations: * – p<0.05 reliable difference of findings in experimental groups in comparison with 
control 2; Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction, Tukey-Kramer one-way ANOVA) 
Fig. 6. Effect of baclofen on the formation of DHR, PHAR and on phagocytic activity of 
neutrophils when administered at different times in relation to immunosuppression 
induction 
As for humoral immunoreactivity, phenibut showed both an immunoprotective and 
immunotherapeutic effect: a reliable increase in the antibody level more than twice in 
comparison with control 2 (p2<0.05) (fig. 5) upon preventive administration of the 
www.intechopen.com
 
Immunotropic Properties of GABA-ergic Agents in Suppression 
 
117 
substance (three days prior to immunopathology induction) and upon its introduction to 
the productive phase of immunogenesis (three days after immunization and 
immunopathology induction). Phagocytic count and phagocytic index, parameters of 
nonspecific resistance, were also sensitive to the corrective effect of phenibut, but the 
effect of the drug was only manifest upon its administration on the day of the antigen and 
cytostatic exposure; at that time the indices of phagocytosis were virtually the same as in 
intact animals (p2<0.05). 
Thus the obtained results permit a conclusion that phenibut is capable of preventing the 
development of disturbances in all the components of the immune system under study, but 
this only occurs upon its administration on the day of immunization and of exposure to an 
immunopathology inductor. 
An assessment of baclofen impact on the immunity status of animals with 
immunosuppression by cyclophosphamide upon administration at different times in 
relation to immunization and pathology simulation showed that the drug was only 
capable of displaying an immunocorrective effect either upon simultaneous 
administration with an immunodepressant agent or after the onset of a lesion. In the 
before-mentioned groups of animals the DHR index, antibody titer and the number of 
neutrophils participating in phagocytosis exceeded reliably the same parameters in 
animals with an immunity disorder  (p2<0.05) achieving background values of immune 
response in control 1 (fig. 6). 
Thus the findings obtained in the course of studying the temporal dependence of 
immunocorrective effects of baclofen indicate that the drug exerts an immunotherapeutic 
effect while administration of baclofen for prevention of immunity disturbances in 
conditions of CPA-induced immunosuppression turned out to be ineffective. 
3.4 The immunomodulating activity of GABA derivatives when introduced during a 
peroral course of treatment 
The third series of experiments was devoted to studying the extent of immunomodulating 
effects of phenotropil, phenibut and baclofen upon their peroral administration over a 14-
day course of therapy. 
In conditions of immunosuppression, peroral administration of phenotropil and phenibut in 
a course led to a restoration of cellular immunoreactivity: the index of delayed-type 
hypersensitivity exceeded the corresponding values in control 2 (p2<0.05) twice achieving 
the values displayed by intact animals. Baclofen showed no effect in relation to the studied 
parameter (fig. 7). 
An estimation of the effect of substances of these experimental series on the humoral link of 
immunogenesis showed that phenotropil displayed the most effect in conditions of 
immunosuppression exerting a stimulating effect on the process of sheep erythrocyte-
specific antibody formation. Thus the hemagglutinin titer in the reaction of passive 
hemagglutination exceeded that of control 2 animals 3.8 times (p2<0.05) and 1.6 times – 
that of intact animals (p2<0.05). Administration of phenibut also promoted a more than 
two-fold elevation of the level of anti-erythrocytic antibodies in comparison with the 
animals receiving the CPA immunodepressant (p2<0.05). As for baclofen, it showed no 
activity in relation to the humoral link of immunogenesis in conditions of 
immunosuppression (fig. 7). 
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The nonspecific link of immunogenesis was also sensitive to the corrective effect of the 
substances under study. Thus phenotropil, phenibut and baclofen caused an intensification 
of phagocytosis (of phagocytic index and phagocytic number as well) in comparison with 
these parameters in immunosuppressed animals, and the intensity of phagocytosis virtually 
achieved the background values in control 1 (p2<0.05) (fig. 7). 
Therefore, the findings of the study of the effect of substances on the values of immune 
response upon peroral administration for 14 days indicated that the most activity upon 
administration in a course was shown by phenotropil and phenibut; these drugs eliminated 
the CPA-induced suppression of the cellular, humoral and nonspecific links of the 
immunity. 
 
 
Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA); 3 – phenotropil (25 mg/kg) 
+ CPA; 4 – phenibut (25 mg/kg) + CPA; 5 – baclofen (2 mg/kg) + CPA 
Designations: Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction and Newman-Keuls test for multiple comparisons); * – p<0.05 reliable difference 
in comparison with control 2 (Student t-criterion with Bonferroni correction and Newman-Keuls test for 
multiple comparisons) 
Fig. 7. Effect of GABA derivatives after a 14-day peroral administration on the formation of 
PHAR, DHR and on phagocyric activity of neutrophils in peripheral blood of animals with 
CPA - induced immunosuppression 
3.5 Influence of GABA derivatives on leukopoiesis and on lymphoproliferative and 
biochemical processes in the immunocompetent organs in conditions of 
immunosuppression 
In the fourth series of experiments we studied the effect of phenotropil, phenibut and 
baclofen on leukopoiesis and on lymphoprolifertaive processes in immunocompetent 
organs (thymus, the spleen) in conditions of immunosuppression. In these series the 
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substances under study were introduced intraperitoneally for five days in the most active 
doses (first administration two days prior to CPA). Animals’ blood sampling was done on 
the next day after the last administration of the substances under study (Samotrueva M.A. et 
al., 2008; Tyurenkov I.N. et al., 2009; Samotrueva M.A. et al., 2011). 
An assessment of the effect of drugs under study on the total number and qualitative 
composition of leukocytes in peripheral blood showed that under the impact of CPA the 
administration of phenotropil resulted in an increase of the total leukocyte number up to 
background values of control 1(p2<0.05). Neither phenibut nor baclofen caused any 
significant change in the total leukocyte number in comparison with the group of 
immunosuppressed animals (p>0.05) (tab. 1). 
 
Experimental groups Total leukocyte number, x 109/L 
Control 1 (physiological saline) 10.8 ± 0.7 
Control 2 (CPA, 150 mg/kg) 8.3 ± 0.7 Δ 
Phenibut (25 mg/kg) + CPA (150 mg/kg) 8.9 ± 0.3 
Phenotropil (25 mg/kg) + CPA (150 mg/kg) 10.4 ± 0.4* 
Baclofen (2 mg/kg) + CPA (150 mg/kg) 9.6 ± 1.1 
The degree of credibility Δ – p<0.05 – in relation to control 1 and * – p<0.05 – in relation to control 2 
(Student t-criterion with Bonferroni correction for multiple comparisons) 
Table 1. Effect of GABA derivatives on total leukocyte count in animals with CPA -induced 
immunosuppression 
In animals with CPA -induced immunological insufficiency a restoration of leukocyte 
population composition was only noted under the impact of phenotropil administration 
when a relative number of leukocytes was noted to increase; the content of lymphoid cells in 
peripheral blood of mice of experimental groups considerably exceeded this parameter in 
control 2 animals (p2<0.05). Administration of baclofen was accompanied by an elevation of 
the number of mature segmented neutrophils (p2<0.05), while the level of lymphocytes 
remained within the range of values typical of immunosuppressed animals (p>0.05). No 
significant changes in the leukogram were noted under the impact of phenibut (p>0.05) (fig. 
8). 
Thus phenotropil displayed the most activity in relation to the leukogram parameters by 
promoting a restoration of leukopoiesis processes which was manifested in an elimination 
of the inhibiting effect of CPA on the lymphoid hematopoietic lineage. 
The results of studying the effects of phenotropil, phenibut and baclofen on 
lymphoproliferative and biochemical processes in immunocompetent organs in conditions 
of CPA -induced immunosuppression indicate that the drugs produce a corrective effect on 
the morphometric parameters which was evident from the increase in thymus and spleen 
weight, a restoration of their cellular composition (p2<0.05) (fig. 9-11). 
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Designations: Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction and Newman-Keuls test for multiple comparisons); * – p<0.05 reliable difference 
in comparison with control 2 (Student t-criterion with Bonferroni correction and Newman-Keuls test for 
multiple comparisons) 
Fig. 8. Effect of GABA derivatives on various leukocyte populations in the leukogram in 
animals with CPA -induced immunosupression 
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Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA + physiological saline); 3 – 
phenotropil (25 mg/kg) + CPA; 4 – phenibut (25 mg/kg) + CPA; 5 – baclofen (2 mg/kg) + CPA 
Designations: Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction and Newman-Keuls test for multiple comparisons); * – p<0.05 reliable difference 
in comparison with control 2 (Student t-criterion with Bonferroni correction and Newman-Keuls test for 
multiple comparisons) 
Fig. 9. Effect of GABA derivatives on the weight and cellularity of immunocompetent 
organs in animals with CPA-induced immunosuppression 
 
 
Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA); 3 – phenotropil (25 mg/kg) 
+ CPA; 4 – phenibut (25 mg/kg) + CPA; 5 – baclofen (2 mg/kg) + CPA 
Designations: Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction and Newman-Keuls test for multiple comparisons); * – p<0.05 reliable difference 
in comparison with control 2 (Student t-criterion with Bonferroni correction and Newman-Keuls test for 
multiple comparisons) 
Fig. 10. Effect of GABA derivatives on lipid peroxidation and catalase activity in the spleen 
of animals with CPA -induced immunosuppression 
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Experimental groups: 1 – control 1 (physiological saline); 2 – control 2 (CPA); 3 – phenotropil (25 mg/kg) 
+ CPA; 4 – phenibut (25 mg/kg) + CPA; 5 – baclofen (2 mg/kg) + CPA 
Designations: Δ – p<0.05 reliable difference in comparison with control 1 (Student t-criterion with 
Bonferroni correction and Newman-Keuls test for multiple comparisons); * – p<0.05 reliable difference 
in comparison with control 2 (Student t-criterion with Bonferroni correction and Newman-Keuls test for 
multiple comparisons) 
Fig. 11. Effect of GABA derivatives on lipid peroxidation and catalase activity in the thymus 
of animals with CPA-induced immunosuppression 
4. Conclusion 
We would like to highlight the importance and urgency of the problem under discussion. 
Immune imbalance underlies the pathogenesis of CNS diseases (depression, disorder of 
cerebral circulation, epilepsy, multiple sclerosis, Alzheimer’s disease, schizophrenia, etc.), 
and one of the causes of these conditions is dysregulation of GABA-ergic system as one of 
the key factors of neuro-immune interactions. An analysis of our own data and those from 
literature permits a conclusion that a realization of immunoactive properties of GABA-ergic 
substances is mediated by both central and direct impact on the corresponding receptors of 
effector cells in the immune system. The pronounced immunomodulating effect of 
phenotropil, phenibut and baclofen that we showed in CPA-induced immunosuppression 
widens the range of their possible administration not only in CNS diseases that are often 
accompanied by immune status disturbances, but also in the immune system diseases 
accompanied by suppression of certain immunogenesis links. 
1. GABA derivatives – phenotropil, phenibut and baclofen – reduce the manifestations of 
immunosuppression induced by CPA administration. 
2. Phenotropil at a dose of 25 mg/kg, 50 mg/kg and baclofen at a dose of 2 mg/kg 
produce the most pronounced immunomodulating effect in conditions of CPA-induced 
immunosuppression. 
3. Immunotropic effects of phenotropil and phenibut are most pronounced upon their 
preventive administration prior to CPA-induced immunosuppression, while the effect 
www.intechopen.com
 
Immunotropic Properties of GABA-ergic Agents in Suppression 
 
123 
of baclofen is most pronounced upon its therapeutic administration when the immune 
system disease is already in progress. 
4. All the substances studied in this work can restore lymphorpoliferative processes and 
normalize the parameters of lipid peroxisation in the immunicompetent organs (thymus 
and spleen); while only phenotropil was able to eliminate the disturbances of 
leukopoietic processes due to immunosuppression. 
5. The immunomodulating effect of phenotropil, phenibut and baclofen established in our 
study as well as their neurotropic effects established by many researchers, allow an 
inclusion of GABA derivatives into a new class of neuroimmunomodulating agents. 
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